Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05059262
Title Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor (MOTION)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Deciphera Pharmaceuticals LLC
Indications

tenosynovial giant cell tumor

Therapies

Vimseltinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.